The Role of Extracellular Vesicles in Liver Fibrosis: Friends or Foes? DOI Creative Commons
Xiang Tao, Can Chen, Mei Liu

et al.

Biomedicines, Journal Year: 2024, Volume and Issue: 12(12), P. 2665 - 2665

Published: Nov. 22, 2024

Liver fibrosis represents a common pathway in the progression of various chronic liver diseases towards cirrhosis and failure. Extracellular vesicles (EVs) are membrane-enclosed particles secreted by diverse cell types, including exosomes, microvesicles, apoptotic vesicles, recently identified migrasomes. These can be taken up recipient cells, thereby modulating their function through transport cargo molecules. EVs facilitate intercellular communication play significant role development fibrosis. Moreover, detection body fluids offers sensitive diagnostic tools for assessing Additionally, may serve as therapeutic targets, potential agents, drug delivery vehicles. This article reviews recent advances field concerning related diseases, with particular focus on newly discovered migrasomes intracellular crosstalk within liver.

Language: Английский

Carboxymethyl chitosan/oxidized hyaluronic acid hydrogel-encapsulated hucMSC-derived exosomes for enhanced hepatic regeneration and post-hepatectomy applications DOI Creative Commons
Qiuxia Zheng, Jia Yao,

Zongbin Sun

et al.

Carbohydrate Polymers, Journal Year: 2025, Volume and Issue: 353, P. 123248 - 123248

Published: Jan. 13, 2025

Language: Английский

Citations

2
Cutting-edge insights into liver fibrosis: advanced therapeutic strategies and future perspectives using engineered mesenchymal stem cell-derived exosomes DOI Creative Commons
Manar A. Didamoony, Ayman A. Soubh, Lamiaa A. Ahmed

et al.

Drug Delivery and Translational Research, Journal Year: 2025, Volume and Issue: unknown

Published: Jan. 24, 2025

Abstract Liver fibrosis is still a serious health concern worldwide, and there increasing interest in mesenchymal stem cells (MSCs) with tremendous potential for treating this disease because of their regenerative paracrine effects. Recently, many researches have focused on using the released exosomes (EXOs) from to treat liver rather than parent themselves. MSC-derived EXOs (MSC-EXOs) demonstrated favourable outcomes similar cell treatment terms regenerative, immunomodulatory, anti-apoptotic, anti-oxidant, anti-necroptotic, anti-inflammatory anti-fibrotic actions several models fibrosis. are superior terms, including lower immunogenicity risk tumour formation. However, maintaining stability efficacy after vivo transplantation remains major challenge clinical applicability. Therefore, strategies been applied engineering, such as parental modification or modifying directly achieve optimum performance Herein, we discuss underlying mechanisms an overview available therapies, among them EXOs. We also summarise recent developments improving effectiveness advantages limitations these approaches upcoming applications. Graphical

Language: Английский

Citations

1
Human umbilical cord-derived mesenchymal stem cells attenuate hepatic stellate cells activation and liver fibrosis DOI Creative Commons
Xiaoyu Shi, Kun Zhang, Qi Qi

et al.

Molecular Biology Reports, Journal Year: 2024, Volume and Issue: 51(1)

Published: June 14, 2024

Abstract Background Liver cirrhosis, a prevalent chronic liver disease, is characterized by fibrosis as its central pathological process. Recent advancements highlight the clinical efficacy of umbilical cord mesenchymal stem cell (UC-MSC) therapy in treatment cirrhosis. Methods and results We investigated pharmacodynamic effects UC-MSCs MSC conditional medium (MSC-CM) vivo, utilizing carbon tetrachloride (CCl 4 )-induced fibrotic rat model. Concurrently, we assessed vitro impact MSCs MSC-CM on various cellular process hepatic stellate cells (HSCs), including proliferation, apoptosis, activation, immunomodulatory capabilities, inflammatory factor secretion. Our indicate that both significantly ameliorate extent animal tissues, reducing collagen content, serum biochemical indices biomarkers. In vitro, inhibited activation HSC line LX-2. Notably, modulated expression type I procollagen TGFβ-1 while increasing MMP1 expression. This modulation restored MMP1/TIMP1 ratio imbalance extracellular matrix deposition induced fibrosis. Both not only apoptosis HSCs but also suppressed proliferation cytokine release from activated HSCs. Furthermore, exerted suppressive effect total lymphocyte activation. Conclusions primarily modulate severity regulating study provides vivo evidence supporting use treatment.

Language: Английский

Citations

5
Extracellular vesicles: emerging therapeutic agents for liver fibrosis DOI Open Access
Giulia Chiabotto,

Armina Semnani,

Elena Ceccotti

et al.

Extracellular Vesicles and Circulating Nucleic Acids, Journal Year: 2025, Volume and Issue: 6(2), P. 216 - 44

Published: May 7, 2025

Liver fibrosis is a progressive condition characterized by excessive scar tissue buildup, leading to impaired liver function and potentially cirrhosis. Despite advancements in treatment strategies, effective anti-fibrotic therapies remain an urgent unmet need. Recent research has identified extracellular vesicles (EVs) as promising therapeutic agents due their ability mediate intercellular communication regulate key fibrotic pathways. This review aims provide comprehensive overview of the potential EVs different vitro vivo models hepatic fibrosis, focusing on natural effects recent engineering for enhanced efficacy. can be derived from various cellular sources, including mesenchymal stromal cells (MSCs) liver-resident cells. Biological materials, serum, breast milk, bacteria, plants, also serve EV sources. Among these, MSC-EVs stand out potential, which significantly through preconditioning with inflammatory signals, pharmacological agents, or genetic improve quality Engineering techniques have further expanded applications, enabling use precise drug-delivery vehicles. Approaches such loading compounds, designing customized EVs, creating EV-liposome hybrids enable targeted delivery activated stellate (HSCs), central drivers progression. These strategies enhance efficacy EV-based treatments. Both engineered critical pathways development, activation HSCs, modulation pro-fibrotic genes, matrix deposition, programmed cell death. Additionally, modulate immune responses, fostering microenvironment conducive repair regeneration. Combining regenerative properties innovative provides highly targeted, approaches restore address need chronic disease therapies.

Language: Английский

Citations

0
Nano-encapsulation of drugs to target hepatic stellate cells: Toward precision treatments of liver fibrosis DOI
Yue Yuan, Jiaxuan Li, Min Chen

et al.

Journal of Controlled Release, Journal Year: 2024, Volume and Issue: 376, P. 318 - 336

Published: Oct. 18, 2024

Language: Английский

Citations

0
The Role of Extracellular Vesicles in Liver Fibrosis: Friends or Foes? DOI Creative Commons
Xiang Tao, Can Chen, Mei Liu

et al.

Biomedicines, Journal Year: 2024, Volume and Issue: 12(12), P. 2665 - 2665

Published: Nov. 22, 2024

Liver fibrosis represents a common pathway in the progression of various chronic liver diseases towards cirrhosis and failure. Extracellular vesicles (EVs) are membrane-enclosed particles secreted by diverse cell types, including exosomes, microvesicles, apoptotic vesicles, recently identified migrasomes. These can be taken up recipient cells, thereby modulating their function through transport cargo molecules. EVs facilitate intercellular communication play significant role development fibrosis. Moreover, detection body fluids offers sensitive diagnostic tools for assessing Additionally, may serve as therapeutic targets, potential agents, drug delivery vehicles. This article reviews recent advances field concerning related diseases, with particular focus on newly discovered migrasomes intracellular crosstalk within liver.

Language: Английский

Citations

0